Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment
Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment is organized by PVI, PeerView Institute for Medical Education.
Activity Release Date: March 2, 2023
Activity Expiration Date: March 1, 2024
Activity Description:
As the cancer immunotherapy arsenal and its impact on patient care continues to expand, it’s more important than ever to refine testing for predictive biomarkers to guide patient selection and clinical decisions about treatment. Assessments of PD-L1 expression and MSI/MMR or TMB status have a role in some tumor types and treatment settings, but a number of challenges related to testing and interpretation of results remain, and better predictive tools are needed. There is also an increasing need for new ways to measure response to immunotherapies as they transition to early-stage, curative-intent settings in different solid tumors. Pathologic response assessment has emerged as a promising approach for evaluating the impact of neoadjuvant immunotherapy in lung, breast, and other cancers. However, limited guidance has been available on how to define and measure pathologic response, and report and apply assessment results.
Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Describe the recommendations and practical considerations for cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings
• Perform appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings
• Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, pulmonologists, • surgeons, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making across different tumors and treatment settings.